Medoxa (Oxaliplatin)

• Oxaliplatin is used in colorectal cancer treatment protocols, targeting tumor cells through DNA cross‑linking.
• Colorectal cancer (adjuvant setting): administered after surgical resection to lower recurrence risk and improve disease‑free survival.
• Metastatic colorectal cancer: used in combination regimens to shrink tumors, alleviate symptoms, and prolong overall survival.
• Neoadjuvant colorectal cancer: given before surgery to downstage tumors and increase resectability.
• Advanced colorectal cancer: incorporated with targeted agents to enhance response rates in refractory disease.

• Oxaliplatin exerts its antineoplastic effect by forming covalent bonds with nucleophilic sites on DNA, creating intra‑ and interstrand cross‑links. These cross‑links obstruct DNA replication and transcription, triggering cell‑cycle arrest and apoptosis in rapidly dividing tumor cells. The platinum‑based adducts are recognized as DNA damage, activating repair pathways that ultimately lead to irreversible cellular injury when the damage exceeds repair capacity.

Oxaliplatin therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset occurring during or after infusion.
• Peripheral neuropathy: tingling or numbness in hands and feet, often dose‑related.
• Fatigue: generalized tiredness affecting daily activities.
• Myelosuppression (neutropenia, anemia, thrombocytopenia): reduced blood cell counts.
• Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: anaphylaxis or bronchospasm requiring immediate treatment.
• Acute cardiac events: arrhythmias or myocardial ischemia observed during infusion.
• Pulmonary toxicity: interstitial pneumonitis or respiratory distress.
• Tumor lysis syndrome: rapid tumor breakdown leading to metabolic disturbances.

Prior to initiating oxaliplatin, clinicians should evaluate patient-specific factors and monitor for potential complications.

• Renal function: assess baseline creatinine clearance and adjust therapy if impairment is present.
• Hepatic function: monitor liver enzymes, as dysfunction may increase toxicity.
• Peripheral neuropathy: perform baseline neurological exam and discontinue if severe symptoms develop.
• Hypersensitivity: be prepared to manage infusion‑related allergic reactions with emergency medications.
• Pregnancy and lactation: avoid use unless the potential benefit justifies the risk to the fetus or infant.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Oxaliplatin may interact with other medications, altering efficacy or increasing toxicity.

Major Interactions (Avoid)

• Concurrent platinum agents: additive nephrotoxicity and neurotoxicity.
• Nephrotoxic drugs (e.g., aminoglycosides, cisplatin): heightened risk of renal impairment.
• Live vaccines: immunosuppression may reduce vaccine effectiveness.
• High‑dose calcium channel blockers: may interfere with drug clearance.

Moderate Interactions (Monitor Closely)

• Antiemetics such as ondansetron: potential QT‑interval prolongation.
• Anticoagulants (warfarin, direct oral anticoagulants): monitor coagulation parameters for bleeding risk.